When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential ...

Rocky Mountain MS Clinic opened a location in Lehi this week, filling a gap in care for patients who have traveled hours or ...

Anti-CD20 therapies, a type of MS treatment, changes levels and profiles of several immune cells in people with MS, a study ...

Multiple sclerosis (MS) is a chronic inflammatory disorder that is thought to impact about 2.3 million people around the ...

Multiple Sclerosis, the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. The rising prevalence of multiple sclerosis (MS) is ...

CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of dimethyl fumarate delayed-release capsules. Dimethyl ...

Neurological diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, pose a significant global health challenge due to their complex pathogenesis and widespread ...

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging ...

Explore Our Free-Market Analysis Sample – Instant Access: – https://www.astuteanalytica.com/request-sample/amyotrophic-lateral-sclerosis-treatment-market ...

A multiple sclerosis specialist shares insights on quiet progression, and discusses research and treatments for MS activity without relapses.

A study of twins reveals two gut bacteria linked to multiple sclerosis, offering new targets for future treatments.